Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity-Reference-Cited by-同舟云学术

Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity

Published:2018-11-07 Issue:12 Volume:9 Page:1230-1234
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Fell Jay B.¹^ORCID,Fischer John P.¹,Baer Brian R.¹,Ballard Joshua¹,Blake James F.¹,Bouhana Karyn¹,Brandhuber Barbara J.¹,Briere David M.²,Burgess Laurence E.¹,Burkard Michael R.¹,Chiang Harrah²,Chicarelli Mark J.¹,Davidson Kevin¹,Gaudino John J.¹,Hallin Jill²,Hanson Lauren¹,Hee Kenneth¹,Hicken Erik J.¹,Hinklin Ronald J.¹,Marx Matthew A.²^ORCID,Mejia Macedonio J.¹,Olson Peter²,Savechenkov Pavel¹,Sudhakar Niranjan²,Tang Tony P.¹,Vigers Guy P.¹,Zecca Henry¹,Christensen James G.²

Affiliation:

1. Array BioPharma, Inc., 3200 Walnut Street, Boulder, Colorado 80301, United States

2. Mirati Therapeutics, Inc., 9393 Towne Centre Drive, Suite 200, San Diego, California 92121, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.8b00382

Reference12 articles.

1. Cancer: The Ras renaissance

2. Drugging RAS: Know the enemy

3. Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers;European Journal of Medicinal Chemistry;2024-11

2. Design, synthesis, characterization, molecular docking studies and biological evaluation of 5, 6, 7, 8-tetrahydropyrido[3,4-d]pyrimidine derivatives as antimicrobial agents;Chemical Data Collections;2024-10

3. Recent advances in the design of small molecular drugs with acrylamides covalent warheads;Bioorganic & Medicinal Chemistry;2024-10

4. Contribution of Noncovalent Recognition and Reactivity to the Optimization of Covalent Inhibitors: A Case Study on KRas^G12C;ACS Chemical Biology;2024-07-11

5. Discovery of novel coumarin-based KRAS-G12C inhibitors from virtual screening and Rational structural optimization;Bioorganic Chemistry;2024-07